| Prev Close: | 88.59 |
|---|---|
| Open: | 88.70 |
| Bid: | 88.75 x 1000 |
| Ask: | 88.76 x 200 |
| 1y Target Est: | 86.50 |
| Beta: | 0.48 |
| Next Earnings Date: | 15-Jul-13 |
| Day's Range: | 88.61 - 89.90 |
|---|---|
| 52wk Range: | 61.71 - 89.90 |
| Volume: | 9,352,740 |
| Avg Vol (3m): | 9,717,350 |
| Market Cap: | 249.46B |
| P/E (ttm): | 24.11 |
| EPS (ttm): | 3.68 |
| Div & Yield: | 2.64 (3.00%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Exxon Mobil Gives $500K to Oklahoma Relief and 2 Other Dow Movers to Watchat Wall St. Cheat Sheet(Wed 2:22PM EDT)
- Apple Still Hedge Funds' Most Popular Stock, But AIG Matters Moreat Barrons.com(Wed 1:48PM EDT)
- Is There Growth Left in Massive Drug Stocks?at Motley Fool(Wed 1:30PM EDT)
- Midday Glance: Pharmaceuticals companiesAP(Wed 1:17PM EDT)
- Midday Glance: Medical Devices companiesAP(Wed 1:17PM EDT)
- Midday Movers: GE, OPEN, CTRX & Moreat CNBC(Wed 1:16PM EDT)
- Equities Can Rise Another 5%-10% On Bernanke's Commentsat Seeking Alpha(Wed 12:59PM EDT)
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Saysat Bloomberg(Wed 11:45AM EDT)
- [video] Benefiting From the Rotation To Cyclicalsat TheStreet(Wed 11:42AM EDT)
- Medtronic Still Reporting Weak Growth, But A Relatively Rare Bargainat Investopedia(Wed 11:35AM EDT)
- Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrowat TheStreet(Wed 11:00AM EDT)
- Early Glance: Pharmaceuticals companiesAP(Wed 10:51AM EDT)
- Early Glance: Medical Devices companiesAP(Wed 10:51AM EDT)
- Swiss Billionaires Buy Merck Geneva Building for Biotech Campusat Bloomberg(Wed 10:39AM EDT)
- 5 Stocks Going Ex-Dividend Tomorrow: SMG, FMER, AIZ, KEY, JNJat TheStreet(Wed 10:00AM EDT)
Press Releases
- Cordis Showcases Cardiovascular Innovations at EuroPCR 2013Business Wire(Tue, May 21)
- Biosense Webster Reports Compelling Results from Ground-Breaking SMART-AF IDE Study on the Safety and Effectiveness of the THERMOCOOL® SMARTTOUCH™ CatheterBusiness Wire(Mon, May 13)
- First Patient Enrolled in reMARQable Clinical Study Evaluating the Safety and Efficacy of Multi-Electrode nMARQ™ Pulmonary Vein Isolation System™ in the Treatment of Paroxysmal Atrial FibrillationBusiness Wire(Thu, May 9)
Reports
- JNJ: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 22)
- Thomson Reuters Stock Report - JOHNSON & JOHNSON (JNJ-N)Thomson Reuters Stock Report(May 22)
- Trading Report for (JNJ). A detailed report, including free correlated market...Stock Traders Daily(May 22)